The hydatid cyst is a cosmopolitan parasitic infection caused by tapeworms of the genus Echinococcus and is a major public health problem in developing countries. Solitary hydatid cysts located in the buttocks are very rare, and the unusual location of the cyst can aid in the differential diagnosis of subcutaneous masses in this area, particularly in endemic areas. In this report, we present the case of a 39-year-old man who was admitted to the emergency department with a painful, abscessed cyst in the buttock region. The cyst was completely excised, and histopathological examination confirmed the diagnosis of a hydatid cyst. Further investigations did not reveal any other locations. Although the buttock region is an extremely rare site of infection for a hydatid cyst, it should be considered in cystic lesions, especially in endemic areas.

The coronavirus disease 2019 (COVID-19) has spread over the majority of countries and it was declared as a pandemic on March 11th, 2020 by The World Health Organization. The number of infected people worldwide is still in progress. Patients diagnosed with cancer are a fragile population because of their chronic disease and related treatments, and therefore, requiring a particular management. Several international initiatives from scientific societies and working groups have provided updated guidance to improve the medical treatments of breast cancer. These recommendations aimed to mitigate the negative effects of this outbreak on prevention, diagnosis, and treatments. Notably, this should be used for prioritizing the various aspects of cancer care particularly breast cancer patients’ safety. In this editorial, we shortly review the current guidelines for breast cancer management during this pandemic and illustrate the available treatments that should be prioritized. We believe this paper will be useful for young oncologists and physicians dealing with this emerging life-threatening disease.

Ovarian granulosa cell tumors are rare gynecological cancers with favorable clinical evolution and survival outcomes. We report a new case of this presentation in a patient that was initially diagnosed as a bilateral primary melanoma of the ovary. The patient is a 51-year-old woman with a history of abdominal swelling and deterioration of her general conditions. Physical examination revealed abdominal distension and diffuse dullness with initially highly elevated cancer antigen 125. Contrast-enhanced thoracoabdominal-pelvic computed tomography showed a left-sided ovarian mass and abundant ascites and pleurisy. Ex-lap surgery found two large bilateral ovarian masses associated with peritoneal carcinomatosis and highly abundant ascites. The histopathological examination of the omental biopsy revealed an undifferentiated tumor proliferation of cells with highly positive Human Melanoma Black 45 marker in favor of an achromic malignant melanoma according to the pathologist. Because of her advanced disease, the patient received a combination of six cycles of neoadjuvant dacarbazine, cisplatin, and paclitaxel and showed partial response based on the response evaluation criteria in solid tumors, followed by total abdominal hysterectomy and bilateral salpingo-oophorectomy with cytoreductive surgery. Unexpectedly, the histopathological analysis of the surgical specimens was in favor of an advanced adult granulosa cell tumor with positive inhibin B. Our patient is alive at her 13th month of survival and is being followed by the oncology team. The challenges of the pathological diagnosis of this case are discussed. The diagnosis of primary ovarian melanoma should not be based on one immunohistochemical marker only. A single biopsy of omental implants in peritoneal carcinomatosis during ex-lap surgery should be avoided.

Urachal carcinoma is a rare tumor, it represents about 0.5-1% of all bladder malignancies. In the majority of cases it is an adenocarcinoma. For the treatment it is recommended for resectable tumors, a partial cystectomy with resection of the urachal ligament, the bladder dome and umbilicus. There is no standard neoadjuvant or adjuvant treatment, and the combinations of 5-fluoruracil with cisplatin are active in metastatic stage. A higher risk of relapse after surgery has been observed in some situations: positive margins, lymph node involvement, involvement of the peritoneal surface, or in the case of the umbilicus was not resected en-bloc.

In general, metastatic renal cell carcinoma (mRCC) is managed with systemic treatments and cytoreductive nephrectomy is recommended only when it is feasible. Historically, systemic treatment of mRCC was limited to cytokine treatment with interferon (IFN) and interleukin (IL)-2, as chemotherapy was considered to be ineffective in these patients. Bevacizumab in combination with interferon alfa is approved for treatment-nave advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates is 30%. We report a case of a patient who presents a complete response after a nephrectomy and bevacizumab associated to interferon alpha.

Choroidal metastasis is the most frequent ocular tumor. Due to its high vascularity, the choroid is particularly susceptible to hematogenous dissemination of cancer cells. The most common primary tumors in choroidal metastasis are located in the lung for men and the breast for women. We report a patient followed for breast cancer treated in June 2005. She was asymptomatic until February 2016, when she presented a progressive decrease in left eye’s visual acuity and headache. Funduscopic examination showed a left exudative retinal detachment. The brain Magnetic resonance imaging revealed a left choroid metastasis. The total body computer tomography scan showed a many lung, liver, peritoneal and bone metastases. The symptoms were improved after whole-brain radiotherapy and first line systemic chemotherapy based on Bevacizumab and weekly Paclitaxel.